HSV / VZV Detection from Lesions

Background Information

Herpes simplex viruses (HSV) (Types 1 and 2) and Varicella-Zoster virus (VZV) are important causes of vesicular lesions. In many instances, laboratory testing is not needed to prove the presence of the virus. For example, if a patient presents with shingles in a classic dermatomal distribution, then the diagnosis is made based on the clinical findings, and laboratory testing for VZV is not needed. However, in other instances, laboratory testing is essential to demonstrate the presence of the virus (e.g., low level viral shedding from a mucous membrane-associated lesion). Laboratory studies are also important for differentiation of HSV and VZV when the clinical presentation is not characteristic (e.g. shingles in the genital region).

Clinical Indications

**The Symptomatic Patient:** When the cause of vesicular or similar lesion is uncertain, then the HSV/VZV Detection by Nucleic Acid Amplification Test should be ordered.

**The Asymptomatic Patient:** Asymptomatic vaginal shedding of HSV is a risk factor for the baby during delivery. This test is warranted in pregnant women who are near delivery, if there is a concern for the possibility of HSV shedding.

Results and/or Interpretation

Qualitative test results (i.e. Positive or Negative for HSV1, HSV2 or VZV) will be reported.

Limitations of these Assays

The HSV/VZV Detection by Nucleic Acid Amplification Assay has been validated on oral, vaginal and skin specimens, but not for cerebrospinal fluid specimens. For HSV PCR on CSF, HSPCRC should be ordered. For HSV PCR on specimens other than oral, vaginal and skin specimens, PCRHSV should be ordered whereas for VZV PCR, VZPCR should be ordered. Both PCRHSV and VZPCR are send-out tests.

Methodology

The Solana HSV 1+2/ VZV assay is an FDA-approved isothermal amplification assay that detects and differentiates HSV1, HSV2 and VZV. Clinical studies, performed at the Cleveland Clinic (manuscript in preparation), have demonstrated a 94.7% sensitivity and 100% specificity for the detection of HSV with this assay. This was superior assay formerly employed (i.e. HSV ELVIS Test System), which had a sensitivity and specificity of 71.1% and 93.2%, respectively. Similarly, the detection of VZV with Solana was superior to direct immunofluorescence (DFA). The sensitivity/specificity of the Solana assay for the detection of VZV in this study was 95.3%/100%, whereas for DFA these were 71.4%/100%, respectively.

References


4. Solana HSV 1+2/VZV Assay product information and package insert, Quidel, San Diego, CA 92130.
## Test Overview

<table>
<thead>
<tr>
<th>Test Name</th>
<th>HSV 1 &amp; 2/ VZV Amplification-Herpes Simplex Virus and Varicella-Zoster Virus, Molecular Detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordering Mnemonic</td>
<td>HSVVZV</td>
</tr>
<tr>
<td>Methodology</td>
<td>Probe Amplification</td>
</tr>
<tr>
<td>Reference Range</td>
<td>Negative</td>
</tr>
<tr>
<td>Specimen Collection</td>
<td>Swab in Universal Transport Media. Only swabs collected from active cutaneous lesions (vesicles of any skin site) and mucocutaneous lesions are acceptable and include the following specimen sources: genital (penis or vaginal/cervical), skin, nares, ocular and oral lesions.</td>
</tr>
</tbody>
</table>
| Stability | Ambient stability= 48 hours  
Frozen stability= 7 days  
Refrigerated stability= 7 days |
| CPT Code | 87529 (Qty 2) and 87798                                                                          |

---

**Technical Information Contact:**  
Christine Ramsey  
216.445.3309  
RamseyC2@ccf.org

**Scientific Information Contact:**  
Gary W. Procop, MD, MS  
216.444.5879  
procopg@ccf.org